CRISPR

CRISPR1-tgfbr1a

ID

ZDB-CRISPR-210422-6

Name

CRISPR1-tgfbr1a

Previous Names

None

Target

tgfbr1a (1)

Sequence

5' - GGATGATCTTTACCCCC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
bns329	tgfbr1a

Expression

Gene expression in Wild Types + CRISPR1-tgfbr1a

No data available

Phenotype

Phenotype resulting from CRISPR1-tgfbr1a

No data available

Phenotype of all Fish created by or utilizing CRISPR1-tgfbr1a

Phenotype	Fish	Conditions	Figures
bulbus arteriosus ab1-elnb labeling decreased amount, abnormal	tgfbr1a^{bns329/bns329}; s843Tg	standard conditions	Fig. 1 from Bensimon-Brito et al., 2021
bulbus arteriosus lumen dilated, abnormal	tgfbr1a^{bns329/bns329}; s843Tg	standard conditions	Fig. 4 , Fig. 6 from Bensimon-Brito et al., 2021
dorsal aorta blood increased fluid flow, abnormal	tgfbr1a^{bns329/bns329}; s843Tg	standard conditions	Fig. 2 from Bensimon-Brito et al., 2021
blood circulation process quality, exacerbated	tgfbr1a^{bns329/bns329}; s843Tg	chemical treatment: isoprenaline	Fig. 7 from Bensimon-Brito et al., 2021
bulbus arteriosus anatomical space dilated, abnormal	tgfbr1a^{bns329/bns329}; s843Tg	standard conditions	Fig. 1 , Fig. 3 from Bensimon-Brito et al., 2021
blood circulation process quality, abnormal	tgfbr1a^{bns329/bns329}; s843Tg	standard conditions	Fig. 2 , Fig. 6 from Bensimon-Brito et al., 2021
ventral aorta aplastic, abnormal	tgfbr1a^bns329/+; tgfbr1b^bns225/+; s843Tg	chemical treatment: SIS3	Figure 2 from Boezio et al., 2020
bulbus arteriosus increased width, abnormal	tgfbr1a^bns329/+; tgfbr1b^bns225/+; s843Tg	chemical treatment: SIS3	Figure 2 from Boezio et al., 2020
pericardium edematous, abnormal	tgfbr1a^bns329/+; tgfbr1b^bns225/+; s843Tg	chemical treatment: SIS3	Figure 2 from Boezio et al., 2020
bulbus arteriosus smooth muscle cell increased distance bulbus arteriosus smooth muscle cell, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}	standard conditions	Figure 4. from Boezio et al., 2020
bulbus arteriosus smooth muscle cell decreased amount, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; mu293Tg; ncv22Tg	standard conditions	Figure 4. from Boezio et al., 2020
ventral aorta aplastic, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; pd27Tg	standard conditions	Figure 1 from Boezio et al., 2020
bulbus arteriosus inner layer ruptured, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; pd27Tg	standard conditions	Figure 1 from Boezio et al., 2020
pericardium edematous, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; pd27Tg	standard conditions	Figure 1 from Boezio et al., 2020
bulbus arteriosus increased width, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	control	Figure 1 , Figure 2 from Boezio et al., 2020
bulbus arteriosus increased width, exacerbated	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	chemical treatment: SIS3	Figure 2 from Boezio et al., 2020
heart tube endothelial cell ab2-smad3 labeling decreased distribution, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	standard conditions	Figure 2 from Boezio et al., 2020
ventral aorta aplastic, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	chemical treatment: SIS3	Figure 2 from Boezio et al., 2020
bulbus arteriosus endothelial cell increased amount, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	standard conditions	Figure 3 from Boezio et al., 2020
bulbus arteriosus endothelial cell proliferative, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	standard conditions	Figure 3 from Boezio et al., 2020
bulbus arteriosus extracellular matrix ab1-elnb labeling mislocalised, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	standard conditions	Figure 4. from Boezio et al., 2020
ventral aorta aplastic, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	control	Figure 1 , Figure 2 from Boezio et al., 2020
pericardium edematous, exacerbated	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	chemical treatment: SIS3	Figure 2 from Boezio et al., 2020
pericardium edematous, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	control	Figure 1 , Figure 2 from Boezio et al., 2020
bulbus arteriosus extracellular matrix ab1-elnb labeling decreased distribution, abnormal	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; s843Tg	standard conditions	Figure 4. from Boezio et al., 2020
pericardium edematous, ameliorated	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; bns421Tg	standard conditions	Figure 5 from Boezio et al., 2020
bulbus arteriosus endothelial cell proliferative, ameliorated	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; bns421Tg; s843Tg	standard conditions	Figure 5 from Boezio et al., 2020
ventral aorta aplastic/hypoplastic, ameliorated	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; bns421Tg; s843Tg	standard conditions	Figure 5 from Boezio et al., 2020
bulbus arteriosus morphology, ameliorated	tgfbr1a^{bns329/bns329}; tgfbr1b^{bns225/bns225}; bns421Tg; s843Tg	standard conditions	Figure 5 from Boezio et al., 2020

Citations